Proactive Investors - Run By Investors For Investors

4D Pharma says it is unaware of any reasons for recent share price fall

Shares in 4D Pharma closed down 30% on Tuesday but recovered some losses on Wednesday
4D Pharma says it is unaware of any reasons for recent share price fall
The pharmaceutical company also confirmed that all clinical study timelines continue to progress as expected

4D Pharma PLC (LON:DDDD) on Wednesday said it was not aware of any reason for the recent fall in its share price.

The pharmaceutical company also confirmed that all clinical study timelines continue to progress as expected.

READ: 4D Pharma bullish on progress of microbiome-based cancer research

4D Pharma notes the recent fall in its share price and confirms that it is not aware of any company related matter which could be responsible for this price movement. The board also confirms that all clinical study timelines continue to progress as expected,” the company said in a statement.

Shares in 4D Pharma closed down 30% on Tuesday but were 10% up at 98p in late morning trade on Wednesday.

View full DDDD profile View Profile

4D Pharma Timeline

Newswire
June 10 2016

Related Articles

doctor
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics
cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use